Condition
    Limited
    Effectiveness 3/5

    Serrapeptase for Chronic Inflammation

    Serratiopeptidase was withdrawn in Italy after post-authorization studies failed to confirm the anti-inflammatory benefit seen in older, poorly controlled trials.

    Overview

    Serratiopeptidase was withdrawn in Italy after post-authorization studies failed to confirm the anti-inflammatory benefit seen in older, poorly controlled trials.

    Verdict

    Not supported

    The historical evidence does not survive modern scrutiny, and a regulator has already acted on that — we would not recommend it for inflammation.

    How It Works

    In vitro the enzyme hydrolyzes fibrin and inflammatory exudate and may reduce bradykinin signaling, but whether an intact 45-50 kDa protein reaches systemic tissue after oral dosing has never been demonstrated in humans.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Commonly sold at 10-60mg (20,000-120,000 SPU) daily, though efficacy is not established.
    Expected timeframe
    No reliable timeframe

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    The verdict is no. Serrapeptase has been used at 10-60 mg/day (roughly 20,000-120,000 enzyme units) in small, mostly old and poorly controlled studies of post-surgical swelling. There is no good evidence it reduces systemic inflammation or lowers inflammatory markers, and no adequately powered randomised trial supports it. As an orally administered protease, it is largely digested rather than absorbed intact. It is not approved as a drug in the US, UK or EU.
    titration
    Not applicable
    starting dose
    Not applicable

    Evidence

    What the studies say

    Early Japanese and European trials from the 1960s-1980s reported reduced post-surgical swelling and pain, but systematic reviews consistently flag small samples, inadequate blinding, and sponsor involvement. In 2013 Italy's AIFA suspended serratiopeptidase products after required post-authorization efficacy studies did not confirm benefit. A Cochrane-style appraisal of proteolytic enzymes for surgical swelling found no reliable effect. The mechanistic problem is decisive: large proteins are digested rather than absorbed, and pharmacokinetic evidence of intact systemic serrapeptase in humans is essentially absent. Case reports of eosinophilic pneumonitis add a safety concern that a null-efficacy product cannot justify.

    Serratiopeptidase: A systematic review of the existing evidence

    Score: 8/10
    2013
    systematic_review
    0

    Bhagat S, Agarwal M, Roy V

    Most trials of serratiopeptidase were small, of poor methodological quality and short duration, providing insufficient evidence for the claimed anti-inflammatory, anti-oedema and analgesic effects.

    View source

    Comparison of clinical efficacy of methylprednisolone and serratiopeptidase for reduction of postoperative sequelae after lower third molar surgery

    Score: 5/10
    2015
    rct
    n=30

    Chappi DM, Suresh KV, Patil MR +5 more

    Methylprednisolone outperformed serratiopeptidase for reducing postoperative swelling and trismus.

    View source

    Safety

    Caveats

    Avoid entirely if you take anticoagulants or are approaching surgery. Persistent inflammation deserves a diagnosis, not an unproven enzyme.

    Less likely to help if

    Everyone: no controlled evidence supports benefit for inflammation in any group.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.